8-KLeadership ChangesRegulation FDExhibits & Filings

MCKESSON CORP 8-K Report, Executive Changes (Sep 7, 2021)

Filed September 7, 2021For Securities:MCK

Summary

McKesson Corporation (MCK) announced a significant change to its Board of Directors with the election of Dr. Richard H. Carmona, effective September 6, 2021. Dr. Carmona brings a wealth of experience, including his tenure as the 17th Surgeon General of the United States and extensive background in health innovation and public health leadership. His appointment strengthens the Board's expertise in critical areas relevant to McKesson's operations and strategic direction. Dr. Carmona has been deemed an independent director and has been appointed to both the Compensation Committee and the Compliance Committee, indicating his active role in overseeing key governance functions. This expansion of the Board from nine to ten members, coupled with the addition of a director with such a distinguished public health and corporate governance background, signals a commitment to robust oversight and strategic guidance. Investors should view this as a positive development enhancing the Board's capabilities.

Key Highlights

  • 1Dr. Richard H. Carmona elected to the Board of Directors, effective September 6, 2021.
  • 2Dr. Carmona's extensive background includes serving as the 17th U.S. Surgeon General and leadership roles in health innovation.
  • 3The Board determined Dr. Carmona to be an independent director.
  • 4Dr. Carmona appointed as a member of the Compensation Committee and the Compliance Committee.
  • 5The Board size increased from nine to ten members upon his election.
  • 6Dr. Carmona will receive standard compensation for non-employee directors, including an $80,000 annual cash retainer and restricted stock units (RSUs).
  • 7The company issued a press release on September 7, 2021, to announce Dr. Carmona's appointment.

Frequently Asked Questions

Dr. Carmona's appointment is significant due to his extensive experience and distinguished background in public health, including his service as the 17th Surgeon General of the United States. His expertise is expected to provide valuable insights and strengthen the Board's oversight capabilities, particularly in areas related to health and compliance.

Dr. Carmona has been appointed as a member of both the Compensation Committee and the Compliance Committee of the Board.

Dr. Carmona will receive compensation in accordance with McKesson's standard arrangement for non-employee directors. This includes an annual cash retainer of $80,000 (prorated) and restricted stock units (RSUs) valued based on the company's common stock closing price on September 9, 2021.

Yes, Dr. Carmona's election increases the size of the Board of Directors from nine to ten members.